A novel, intelligent, system for remote patient monitoring of asthma and COPD using fast response capnography
Lead Participant:
CAMBRIDGE RESPIRATORY INNOVATIONS LIMITED
Abstract
The WHO estimates that over 7% of the Earth's population suffer from two chronic respiratory conditions: asthma and chronic obstructive pulmonary disease (COPD). The incidence is rising worldwide due to global increases in air pollution and tobacco smoking.
Existing clinical technologies lack the precision, predictive power and usability to deliver sustained real-world impact, resulting in a large care gap. As a result, two thirds of asthma deaths are preventable, and two thirds of patients with COPD are undiagnosed. Asthma and COPD costs the UK economy £5bn each year, and the US economy more than $100bn each year.
Cambridge Respiratory Innovations Limited (CRIL) is a venture-backed respiratory intelligence company, founded in 2013 in Cambridge UK. Our mission is to transform respiratory medicine, through accurate early diagnostics, intelligent remote monitoring, and early prediction of deterioration.
Our N-Tida technologies are built on a foundation of novel, patent-protected, fast-response CO2 sensor technology. Capnometers in clinical use today are based on crude, low-resolution CO2 sensors, often integrated into ventilators, designed to provide very basic information about breathing to clinicians, e.g., breathing rate, and maximum exhaled CO2 at the end of the breath.
Our sensors provide unparalleled sensitivity, high resolution, sampled directly from the mouth. The sensitivity of our sensor enables never-before-seen information, encoded within the shape of the CO2 waveform, related to lung physiology, which no other technology in clinical use today can detect.
We have developed 80 novel respiratory biomarkers, validated through several clinical trials over the past 6 years, which provide novel information about lung health, sensitive to small changes in airway obstruction in patients with asthma and COPD. These biomarkers drive our AI-powered diagnostic, monitoring and predictive software technologies.
Existing clinical technologies lack the precision, predictive power and usability to deliver sustained real-world impact, resulting in a large care gap. As a result, two thirds of asthma deaths are preventable, and two thirds of patients with COPD are undiagnosed. Asthma and COPD costs the UK economy £5bn each year, and the US economy more than $100bn each year.
Cambridge Respiratory Innovations Limited (CRIL) is a venture-backed respiratory intelligence company, founded in 2013 in Cambridge UK. Our mission is to transform respiratory medicine, through accurate early diagnostics, intelligent remote monitoring, and early prediction of deterioration.
Our N-Tida technologies are built on a foundation of novel, patent-protected, fast-response CO2 sensor technology. Capnometers in clinical use today are based on crude, low-resolution CO2 sensors, often integrated into ventilators, designed to provide very basic information about breathing to clinicians, e.g., breathing rate, and maximum exhaled CO2 at the end of the breath.
Our sensors provide unparalleled sensitivity, high resolution, sampled directly from the mouth. The sensitivity of our sensor enables never-before-seen information, encoded within the shape of the CO2 waveform, related to lung physiology, which no other technology in clinical use today can detect.
We have developed 80 novel respiratory biomarkers, validated through several clinical trials over the past 6 years, which provide novel information about lung health, sensitive to small changes in airway obstruction in patients with asthma and COPD. These biomarkers drive our AI-powered diagnostic, monitoring and predictive software technologies.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| CAMBRIDGE RESPIRATORY INNOVATIONS LIMITED | £1,218,531 | £ 852,972 |
People |
ORCID iD |